The GLP-1 Floor Just Got Higher
The commercial case for treating GLP-1 as a structural shift rather than a passing drug cycle got a great deal stronger in May 2026. A clinical trial of orforglipron, a new oral GLP-1 medication recently approved by the FDA in the US, showed that patients who switched from injectable treatments kept off 75 to 79 percent of their lost weight after a further year on the pill, compared with 38 to 49 percent for a placebo group, according to FoodNavigator coverage of the ATTAIN-MAINTAIN trial.
That matters for your commercial planning for two reasons. First, orforglipron is cheaper to produce than injectables and easier to take. If the cost of access falls, the population of long-term users grows faster than current projections suggest. Second, the rebound effect that big food companies had quietly built into their scenarios, the assumption that most users stop and eventually return to prior consumption patterns, now looks unreliable. The ATTAIN-MAINTAIN data suggests sustained appetite suppression is achievable on an ongoing oral regimen.
Circana data places GLP-1 household penetration in the US at roughly 23 percent today, with projections reaching 35 percent by 2030, as reported by Food Dive and cited in prior Circana shopper research. At 35 percent, this is no longer a wellness niche. It is close to a third of all US households with a member whose eating patterns are structurally different from the norm: smaller portions, higher protein density per calorie, lower overall food intake. If oral pills accelerate adoption, the timeline to that figure shortens.
Protein and Fibre Are Now the Shelf's Default Language
GLP-1 is the catalyst, but the demand signal runs broader than drug users alone. The cultural conversation around the drugs has normalised a higher-protein, higher-fibre approach for shoppers who will never take a prescription. You are seeing that in category performance.
In UK grocery, Bio&Me, a fibre and gut-health brand launched in 2019, expects to hit £20 million in sales this year on 45 percent year-on-year growth, according to a Just Food interview with CEO Jon Walsh. Walsh says repeat purchase rates on key lines have climbed above 40 percent and the growth model is shifting from gaining new shelf space to deepening loyalty with existing buyers. That is a meaningful signal: early-adopter health shoppers are not sampling and moving on. They are committing.
The global functional food and beverage market was valued at $438 billion last year and is projected to reach $983 billion by 2034, per Fortune Business Insights data cited by FoodNavigator. Crucially, the vitamins, minerals, and supplements market, valued at $164 billion last year, is not shrinking in response. The two categories are growing alongside each other because they serve different consumer needs: functional food is about living health every day, while supplements are for targeted results. Your category does not need to choose between them. But it does need a clear answer on which lane it owns.
Clean Label Is Now a Regulatory Imperative, Not Just a Marketing Angle
Shopper demand for shorter, simpler ingredient lists has been visible for years. What has changed in 2026 is that regulation is catching up with consumer expectation, which removes the option of waiting.
California's law banning Red No. 3, brominated vegetable oil, potassium bromate, and propylparaben in foods and beverages takes effect January 1, 2027, according to Food Business News coverage of the clean-label regulatory shift. The American Bakers Association expects nearly complete phase-out of azodicarbonamide by the end of this year through a voluntary programme. Manufacturers are also watching California's Proposition 65 for potential action on other compounds including sulfur dioxide and acrylamide found in baked goods.
Reformulation is no longer a scheduled project. It is a continuous condition. Food Business News reporting on reformulation fatigue describes a world where clean-label initiatives, regulatory updates, and new nutrition priorities arrive in overlapping phases rather than coordinated cycles, forcing R&D and marketing teams to work on multiple changes at once. The brands managing this well are those that have built reformulation capacity into their operating model rather than treating each change as a one-off project.
For shopper-marketing teams, the practical implication is that clean-label claims on pack are increasingly table stakes rather than a point of difference. The differentiation opportunity has shifted to transparency and proof: explaining what you changed, why, and what the nutritional outcome is. Shoppers who arrive at the shelf with a health filter will give more weight to a short ingredients list they understand than to a health claim they cannot verify.
How Single-Portion Pack Architecture Is Shifting the Basket
GLP-1 users eat less per sitting. But they still eat frequently, and they still want flavour, convenience, and value per occasion. That combination is pushing demand toward single-serve and smaller-format packs in categories from ambient meals to snacks to beverages.
In UK food retail, Maggi has launched Global Kitchen, a range of six ambient single-serve microwaveable meals that cook in two minutes, each 260g pouch low in saturated fat and carrying at least a protein source, per FoodNavigator NPD coverage. The format targets lunchtime and evening occasions when cooking from scratch is not practical, which maps closely to the eating pattern of a GLP-1 user: small, fast, satisfying, nutritionally credible.
Beverage packaging is also moving in this direction. Packaging is now described as a critical tool for differentiation at the shelf, shaping consumer perception in seconds, according to BeverageDaily coverage of packaging innovation trends. For health-positioned brands, the pack signal matters as much as the product claim. A single-serve format communicates portion awareness. A distinctive shape communicates innovation. Both are working harder on shelf because shoppers are spending less time browsing and more time filtering.
The challenge for your pack architecture is margin. Smaller packs typically cost more per unit to produce and deliver. In a market where food-at-home inflation is already tracking close to 4 percent in 2026 and the Producer Price Index for food surged 2.2 percent year over year in April, per FMI briefing data reported by Food Business News, you need a clear pricing strategy before you launch a smaller SKU. The shopper who wants a single-serve option is often the same shopper managing a tight budget. They will pay a modest premium for health and convenience, but not an unlimited one.
What Brands and Retailers Are Doing Right Now
The supply side is already responding to the health signal in concrete ways. In beverages, Coca-Cola's launch of a probiotic soda reflects the mainstreaming of functional benefits into everyday mass-market formats, as noted by FoodNavigator analysis of the functional and supplements market. The move signals that gut health has cleared the wellness-specialist aisle and is now competing for space in the mainstream cold vault.
In plant-based, US dollar sales fell 2 percent from 2024 to 2025 to $7.9 billion, marking the second consecutive annual decline, per The Good Food Institute's 2026 State of the Industry Report using SPINS data, as reported by Food Business News. The category's health positioning has not been enough to overcome taste and price barriers. That is a useful signal: health intention does not automatically convert to purchase. The product still needs to win on flavour and value. Brands leaning on the health angle alone without solving the eating experience are finding out the hard way.
Kantar's BrandZ data shows that brands combining genuine differentiation with emotional connection can hold pricing power even as shoppers tighten budgets, per FoodNavigator coverage of the BrandZ findings. For health-positioned brands, that emotional connection often lives in the credibility of the health claim: a brand that has demonstrably reformulated, reduced additives, or raised protein content earns more trust than one that badges generic wellness language on an unchanged formula.
What to Watch in the Next 90 Days
Three things are worth tracking closely. First, orforglipron's uptake rate post-FDA approval. If prescriptions ramp quickly, the shift in portion-size demand accelerates on a faster timeline than Circana's 2030 projection assumes. Second, retailer response to California's January 2027 additive deadline: expect accelerated private-label reformulation in the second half of 2026 as retailers race to update their own-brand lines before branded alternatives do. Third, repeat purchase rates in gut-health and high-protein categories. Bio&Me's 40-plus percent repeat rate on key lines is a signal that committed health shoppers are building habits, not just sampling. If that pattern holds across other health-positioned brands, the path to stable margin in this segment is through loyalty, not distribution breadth alone.
The shopper arriving at your shelf in 2026 has already filtered by health before they reach the fixture. Your job is to be the answer that is already waiting for them.